# EIDP, Inc.: financial statements, quarterly

CTA-PB · NYSE · CIK 30554 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cta-pb.md) · [Financials](/companies/cta-pb/financials.md) · [Filings](/companies/cta-pb/filings.md) · [Insiders](/companies/cta-pb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cta-pb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2015 (2015-03-31) | Q2 FY2015 (2015-06-30) | Q3 FY2015 (2015-09-30) | Q4 FY2015 (2015-12-31) | Q1 FY2016 (2016-03-31) | Q2 FY2016 (2016-06-30) | Q3 FY2016 (2016-09-30) | Q4 FY2016 (2016-12-31) | Q1 FY2017 (2017-03-31) | Q2 FY2017 (2017-06-30) | period not labelled (2018-03-31) | Q1 FY2019 (2019-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9,241](/filings/0000030554-15-000020.md) | [8,660](/filings/0000030554-15-000070.md) | [4,873](/filings/0000030554-17-000004.md) | [5,299](/filings/0000030554-17-000004.md) | [7,405](/filings/0000030554-17-000016.md) | [7,061](/filings/0000030554-17-000035.md) | [4,917](/filings/0000030554-17-000004.md) | [5,211](/filings/0000030554-17-000004.md) | [7,743](/filings/0000030554-17-000016.md) | [7,424](/filings/0000030554-17-000035.md) | [6,699](/filings/0000030554-19-000017.md) | [6,288](/filings/0000030554-19-000017.md) |
| Cost of revenue | $m | [4,516](/filings/0000030554-17-000004.md) | [4,103](/filings/0000030554-17-000004.md) | [3,084](/filings/0000030554-17-000004.md) | [3,409](/filings/0000030554-17-000004.md) | [4,242](/filings/0000030554-17-000016.md) | [3,990](/filings/0000030554-17-000035.md) | [3,090](/filings/0000030554-17-000004.md) | [3,147](/filings/0000030554-17-000004.md) | [4,371](/filings/0000030554-17-000016.md) | [4,192](/filings/0000030554-17-000035.md) | [4,847](/filings/0000030554-19-000017.md) | [4,235](/filings/0000030554-19-000017.md) |
| Research and development | $m | [479](/filings/0000030554-16-000121.md) | [495](/filings/0000030554-16-000147.md) | [441](/filings/0000030554-16-000156.md) | [483 d](/filings/0000030554-17-000004.md) | [418](/filings/0000030554-17-000016.md) | [432](/filings/0000030554-17-000035.md) | [410](/filings/0000030554-16-000156.md) | [381 d](/filings/0000030554-17-000004.md) | [416](/filings/0000030554-17-000016.md) | [441](/filings/0000030554-17-000035.md) | [382](/filings/0000030554-19-000017.md) | [355](/filings/0000030554-19-000017.md) |
| Selling, general and administrative | $m | [1,220](/filings/0000030554-16-000121.md) | [1,274](/filings/0000030554-16-000147.md) | [1,046](/filings/0000030554-16-000156.md) | [1,075 d](/filings/0000030554-17-000004.md) | [1,128](/filings/0000030554-17-000016.md) | [1,211](/filings/0000030554-17-000035.md) | [1,016](/filings/0000030554-16-000156.md) | [964 d](/filings/0000030554-17-000004.md) | [1,260](/filings/0000030554-17-000016.md) | [1,348](/filings/0000030554-17-000035.md) | [959](/filings/0000030554-19-000017.md) | [970](/filings/0000030554-19-000017.md) |
| Operating income | $m | [1,941](/filings/0000030554-15-000020.md) | [1,637](/filings/0000030554-15-000070.md) | [580](/filings/0000030554-15-000083.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [530](/filings/0000030554-16-000121.md) | [260](/filings/0000030554-16-000147.md) | [96.0](/filings/0000030554-16-000156.md) | [(190) d](/filings/0000030554-17-000004.md) | [406](/filings/0000030554-17-000016.md) | [306](/filings/0000030554-17-000035.md) | [(69.0)](/filings/0000030554-16-000156.md) | [101 d](/filings/0000030554-17-000004.md) | [224](/filings/0000030554-17-000016.md) | [128](/filings/0000030554-17-000035.md) | [27.0](/filings/0000030554-19-000017.md) | [(40.0)](/filings/0000030554-19-000017.md) |
| Net income | $m | [1,031](/filings/0000030554-16-000121.md) | [940](/filings/0000030554-16-000147.md) | [235](/filings/0000030554-16-000156.md) | [(256)](/filings/0000030554-17-000004.md) | [1,226](/filings/0000030554-17-000016.md) | [1,020](/filings/0000030554-17-000035.md) | [2.0](/filings/0000030554-16-000156.md) | [263](/filings/0000030554-17-000004.md) | [1,113](/filings/0000030554-17-000016.md) | [862](/filings/0000030554-17-000035.md) | [(228)](/filings/0000030554-19-000017.md) | [85.0](/filings/0000030554-19-000017.md) |
| Diluted EPS | $ per share | [1.13](/filings/0000030554-16-000121.md) | [1.03](/filings/0000030554-16-000147.md) | [0.26](/filings/0000030554-16-000156.md) | not reported | [1.39](/filings/0000030554-17-000016.md) | [1.16](/filings/0000030554-17-000035.md) | [0.00](/filings/0000030554-16-000156.md) | not reported | [1.27](/filings/0000030554-17-000016.md) | [0.99](/filings/0000030554-17-000035.md) | not reported | not reported |
| Basic EPS | $ per share | [1.13](/filings/0000030554-16-000121.md) | [1.04](/filings/0000030554-16-000147.md) | [0.26](/filings/0000030554-16-000156.md) | not reported | [1.40](/filings/0000030554-17-000016.md) | [1.16](/filings/0000030554-17-000035.md) | [0.00](/filings/0000030554-16-000156.md) | not reported | [1.28](/filings/0000030554-17-000016.md) | [0.99](/filings/0000030554-17-000035.md) | not reported | not reported |

- Revenue: us-gaap:Revenues, us-gaap:SalesRevenueNet
- Cost of revenue: us-gaap:CostOfGoodsSold, us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2016 (2016-03-31) | Q2 FY2016 (2016-06-30) | Q3 FY2016 (2016-09-30) | FY2016 (2016-12-31) | Q1 FY2017 (2017-03-31) | Q2 FY2017 (2017-06-30) | period not labelled (2017-12-31) | period not labelled (2018-03-31) | period not labelled (2018-06-30) | period not labelled (2018-09-30) | period not labelled (2018-12-31) | Q1 FY2019 (2019-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [4.2](/filings/0000030554-17-000016.md) | [4.4](/filings/0000030554-17-000035.md) | [4.5](/filings/0000030554-16-000156.md) | [4.6](/filings/0000030554-17-000035.md) | [3.3](/filings/0000030554-17-000016.md) | [3.3](/filings/0000030554-17-000035.md) | [7.3](/filings/0000030554-19-000005.md) | [5.1](/filings/0000030554-18-000005.md) | [4.4](/filings/0000030554-18-000009.md) | [3.5](/filings/0000030554-18-000013.md) | [4.5](/filings/0000030554-19-000017.md) | [3.8](/filings/0000030554-19-000017.md) |
| Current assets | $bn | [17.9](/filings/0000030554-16-000121.md) | [18.1](/filings/0000030554-16-000147.md) | [18.3](/filings/0000030554-16-000156.md) | [17.1](/filings/0000030554-17-000035.md) | [19.1](/filings/0000030554-17-000016.md) | [20.1](/filings/0000030554-17-000035.md) | [23.1](/filings/0000030554-19-000005.md) | [21.7](/filings/0000030554-18-000005.md) | [20.1](/filings/0000030554-18-000009.md) | [18.9](/filings/0000030554-18-000013.md) | [18.6](/filings/0000030554-19-000017.md) | [19.2](/filings/0000030554-19-000017.md) |
| Total assets | $bn | [41.8](/filings/0000030554-16-000121.md) | [42.3](/filings/0000030554-16-000147.md) | [42.5](/filings/0000030554-16-000156.md) | [40.0](/filings/0000030554-17-000035.md) | [41.9](/filings/0000030554-17-000016.md) | [43.2](/filings/0000030554-17-000035.md) | [113](/filings/0000030554-19-000005.md) | [112](/filings/0000030554-18-000005.md) | [108](/filings/0000030554-18-000009.md) | [102](/filings/0000030554-18-000013.md) | [101](/filings/0000030554-19-000017.md) | [102](/filings/0000030554-19-000017.md) |
| Current liabilities | $bn | [9.0](/filings/0000030554-16-000121.md) | [8.4](/filings/0000030554-16-000147.md) | [9.1](/filings/0000030554-16-000156.md) | [8.9](/filings/0000030554-17-000035.md) | [9.8](/filings/0000030554-17-000016.md) | [10.4](/filings/0000030554-17-000035.md) | [12.1](/filings/0000030554-19-000005.md) | [12.0](/filings/0000030554-18-000005.md) | [10.9](/filings/0000030554-18-000009.md) | [11.3](/filings/0000030554-18-000013.md) | [11.4](/filings/0000030554-19-000017.md) | [11.9](/filings/0000030554-19-000017.md) |
| Total liabilities | $bn | [31.2](/filings/0000030554-16-000121.md) | [31.7](/filings/0000030554-16-000147.md) | [32.5](/filings/0000030554-16-000156.md) | [29.8](/filings/0000030554-17-000035.md) | [30.2](/filings/0000030554-17-000016.md) | [30.6](/filings/0000030554-17-000035.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $bn | not reported | not reported | not reported | [8.1](/filings/0000030554-17-000004.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $bn | [1.6](/filings/0000030554-16-000121.md) | [2.3](/filings/0000030554-16-000147.md) | [3.2](/filings/0000030554-16-000156.md) | [0.0](/filings/0000030554-17-000004.md) | [2.3](/filings/0000030554-17-000016.md) | [3.5](/filings/0000030554-17-000035.md) | [1.3](/filings/0000030554-19-000005.md) | [3.4](/filings/0000030554-18-000005.md) | [3.7](/filings/0000030554-18-000009.md) | [4.4](/filings/0000030554-18-000013.md) | [0.3](/filings/0000030554-19-000005.md) | [3.2](/filings/0000030554-19-000017.md) |
| Short-term borrowings | $bn | not reported | not reported | not reported | [0.4](/filings/0000030554-17-000004.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [10.4](/filings/0000030554-16-000121.md) | [10.3](/filings/0000030554-16-000147.md) | [9.8](/filings/0000030554-16-000156.md) | [10.0](/filings/0000030554-17-000035.md) | [11.4](/filings/0000030554-17-000016.md) | [12.4](/filings/0000030554-17-000035.md) | [74.8](/filings/0000030554-19-000005.md) | [74.7](/filings/0000030554-18-000005.md) | [72.5](/filings/0000030554-18-000009.md) | [66.7](/filings/0000030554-18-000013.md) | [69.9](/filings/0000030554-19-000017.md) | [69.6](/filings/0000030554-19-000017.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:CommercialPaper
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2015 (2015-03-31) | Q2 FY2015 (2015-06-30) | Q3 FY2015 (2015-09-30) | Q4 FY2015 (2015-12-31) | Q1 FY2016 (2016-03-31) | Q2 FY2016 (2016-06-30) | Q3 FY2016 (2016-09-30) | Q4 FY2016 (2016-12-31) | Q1 FY2017 (2017-03-31) | Q2 FY2017 (2017-06-30) | period not labelled (2018-03-31) | Q1 FY2019 (2019-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2,123)](/filings/0000030554-16-000121.md) | [78.0 d](/filings/0000030554-16-000147.md) | [200 d](/filings/0000030554-16-000156.md) | [4,161 d](/filings/0000030554-17-000004.md) | [(1,806)](/filings/0000030554-17-000016.md) | [346 d](/filings/0000030554-17-000035.md) | [383 d](/filings/0000030554-16-000156.md) | [4,377 d](/filings/0000030554-17-000004.md) | [(1,624)](/filings/0000030554-17-000016.md) | [(2,431) d](/filings/0000030554-17-000035.md) | [(1,975)](/filings/0000030554-19-000017.md) | [(1,422)](/filings/0000030554-19-000017.md) |
| Capital expenditure | $m | [565](/filings/0000030554-16-000121.md) | [373 d](/filings/0000030554-16-000147.md) | [353 d](/filings/0000030554-16-000156.md) | [338 d](/filings/0000030554-17-000004.md) | [357](/filings/0000030554-17-000016.md) | [150 d](/filings/0000030554-17-000035.md) | [252 d](/filings/0000030554-16-000156.md) | [260 d](/filings/0000030554-17-000004.md) | [330](/filings/0000030554-17-000016.md) | [194 d](/filings/0000030554-17-000035.md) | [355](/filings/0000030554-19-000017.md) | [625](/filings/0000030554-19-000017.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [2.0](/filings/0000030554-19-000017.md) | [2.0](/filings/0000030554-19-000017.md) |
| Share repurchases | $m | [282](/filings/0000030554-16-000121.md) | [71.0 d](/filings/0000030554-16-000147.md) | [2,000 d](/filings/0000030554-16-000156.md) | [0.0 d](/filings/0000030554-17-000004.md) | [0.0](/filings/0000030554-16-000121.md) | [0.0 d](/filings/0000030554-16-000147.md) | [416 d](/filings/0000030554-16-000156.md) | [500 d](/filings/0000030554-17-000004.md) | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2013 (2013-09-30) | Q1 FY2014 (2014-03-31) | Q2 FY2014 (2014-06-30) | Q3 FY2014 (2014-09-30) | Q1 FY2015 (2015-03-31) | Q2 FY2015 (2015-06-30) | Q3 FY2015 (2015-09-30) | Q1 FY2016 (2016-03-31) | Q2 FY2016 (2016-06-30) | Q3 FY2016 (2016-09-30) | Q1 FY2017 (2017-03-31) | Q2 FY2017 (2017-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [933](/filings/0000030554-14-000060.md) | [931](/filings/0000030554-15-000020.md) | [926](/filings/0000030554-15-000070.md) | [918](/filings/0000030554-15-000083.md) | [914](/filings/0000030554-16-000121.md) | [912](/filings/0000030554-16-000147.md) | [891](/filings/0000030554-16-000156.md) | [877](/filings/0000030554-17-000016.md) | [879](/filings/0000030554-17-000035.md) | [879](/filings/0000030554-16-000156.md) | [871](/filings/0000030554-17-000016.md) | [873](/filings/0000030554-17-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 100 at 2019-03-31, from the cover of the [10-Q filed 2019-05-08](/filings/0000030554-19-000017.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.